INDRA Trademark

Trademark Overview


On Thursday, August 8, 2024, a trademark application was filed for INDRA with the United States Patent and Trademark Office. The USPTO has given the INDRA trademark a serial number of 98688705. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, February 18, 2025. This trademark is owned by Amplexd Therapeutics, Inc.. The INDRA trademark is filed in the Medical Instrument Products category with the following description:

Light-emitting medical device for treatment of cervical cancer and precursors to cervical cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of penile cancer and precursors to penile cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of vulvar cancer and precursors to vulvar cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of head and neck cancer and precursors to head and neck cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of anal cancer and precursors to anal cancer including high-risk human papillomaviruses; light-emitting medical device and system for treatment of urethral or bladder cancer; light emitting medical device and system for treatment of vaginal bacterial and fungal infections; light emitting medical device and system for treatment of cutaneous or mucosal bacterial and fungal infections; ligh...
indra

General Information


Serial Number98688705
Word MarkINDRA
Filing DateThursday, August 8, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateTuesday, February 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesLight-emitting medical device for treatment of cervical cancer and precursors to cervical cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of penile cancer and precursors to penile cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of vulvar cancer and precursors to vulvar cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of head and neck cancer and precursors to head and neck cancer including high-risk human papillomaviruses; Light-emitting medical device for treatment of anal cancer and precursors to anal cancer including high-risk human papillomaviruses; light-emitting medical device and system for treatment of urethral or bladder cancer; light emitting medical device and system for treatment of vaginal bacterial and fungal infections; light emitting medical device and system for treatment of cutaneous or mucosal bacterial and fungal infections; light emitting medical device and system for treatment of cutaneous or mucosal viral infections; light emitting medical device and system for environmental disinfection; light-emitting medical device and system for treatment of actinic keratoses and other cutaneous precancers.

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, August 8, 2024
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmplexd Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGaithersburg, MD 20878

Trademark Events


Event DateEvent Description
Thursday, August 8, 2024NEW APPLICATION ENTERED
Thursday, January 16, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 13, 2025ASSIGNED TO EXAMINER
Tuesday, February 18, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 18, 2025NON-FINAL ACTION WRITTEN
Tuesday, February 18, 2025NON-FINAL ACTION E-MAILED